Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT01817075 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01817075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01817075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
November 4, 2013
Completion date
March 31, 2020
Enrollment
177 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infection, benign neoplasm, malignant neoplasm, methicillin-resistant staphylococcus aureus infection, myeloid neoplasm, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia